title: Response to commentary: 'If roflumilast inhibits the innate immunity in the stable patient, what about infection?'.
authors.forename: Amparo
authors.initials: A
authors.lastname: Buenestado
authors.forename: Stanislas
authors.initials: S
authors.lastname: Grassin-Delyle
authors.forename: Fleur
authors.initials: F
authors.lastname: Guitard
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Naline
authors.forename: Christophe
authors.initials: C
authors.lastname: Faisy
authors.forename: Dominique
authors.initials: D
authors.lastname: Israël-Biet
authors.forename: Edouard
authors.initials: E
authors.lastname: Sage
authors.forename: Jean François
authors.initials: JF
authors.lastname: Bellamy
authors.forename: Hermann
authors.initials: H
authors.lastname: Tenor
authors.forename: Philippe
authors.initials: P
authors.lastname: Devillier
mesh_terms: D000631:Aminopyridines / Q000008:administration & dosage* / Q000009:adverse effects*; D001549:Benzamides / Q000008:administration & dosage* / Q000009:adverse effects*; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D016867:Immunocompromised Host; D009894:Opportunistic Infections / Q000276:immunology*
chemical_list: D000631:Aminopyridines; D001549:Benzamides